JP2023510797A5 - - Google Patents
Info
- Publication number
- JP2023510797A5 JP2023510797A5 JP2022542408A JP2022542408A JP2023510797A5 JP 2023510797 A5 JP2023510797 A5 JP 2023510797A5 JP 2022542408 A JP2022542408 A JP 2022542408A JP 2022542408 A JP2022542408 A JP 2022542408A JP 2023510797 A5 JP2023510797 A5 JP 2023510797A5
- Authority
- JP
- Japan
- Prior art keywords
- ahr
- patient
- tumor
- staining
- positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959246P | 2020-01-10 | 2020-01-10 | |
| US62/959,246 | 2020-01-10 | ||
| US202063128465P | 2020-12-21 | 2020-12-21 | |
| US63/128,465 | 2020-12-21 | ||
| PCT/US2021/012571 WO2021142180A1 (en) | 2020-01-10 | 2021-01-08 | Ahr inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510797A JP2023510797A (ja) | 2023-03-15 |
| JP2023510797A5 true JP2023510797A5 (enExample) | 2024-01-16 |
Family
ID=74595366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542408A Withdrawn JP2023510797A (ja) | 2020-01-10 | 2021-01-08 | Ａｈｒ阻害剤及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230039711A1 (enExample) |
| EP (1) | EP4087578A1 (enExample) |
| JP (1) | JP2023510797A (enExample) |
| KR (1) | KR20220125323A (enExample) |
| CN (1) | CN115190799A (enExample) |
| AU (1) | AU2021206696A1 (enExample) |
| BR (1) | BR112022013673A2 (enExample) |
| CA (1) | CA3167283A1 (enExample) |
| CL (1) | CL2022001872A1 (enExample) |
| IL (1) | IL294647A (enExample) |
| MX (1) | MX2022008532A (enExample) |
| WO (1) | WO2021142180A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3612030T3 (fi) | 2017-04-21 | 2026-03-20 | Pahr Therapeutics Inc | Ahr:n indoliestäjiä ja niiden käyttötapoja |
| MX2022006308A (es) | 2019-11-26 | 2022-06-22 | Ikena Oncology Inc | Derivados de carbazol polimorfos y usos de los mismos. |
| US12570638B2 (en) | 2020-05-20 | 2026-03-10 | Sail Biomedicines, Inc. | Fused imidazole derivatives as AHR antagonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035288B1 (ru) * | 2010-07-27 | 2020-05-25 | Трастис Оф Бостон Юниверсити | МОДИФИКАТОРЫ АРИЛУГЛЕВОДОРОДНОГО РЕЦЕПТОРА (AhR) В КАЧЕСТВЕ НОВЫХ ПРОТИВОРАКОВЫХ ТЕРАПЕВТИЧЕСКИХ СРЕДСТВ |
| RU2640913C2 (ru) * | 2011-09-07 | 2018-01-12 | Дойчес Кребсфоршунгсцентрум | Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr |
| EA201892666A1 (ru) | 2016-05-25 | 2019-08-30 | Байер Фарма Акциенгезельшафт | 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды |
| WO2018085348A1 (en) | 2016-11-03 | 2018-05-11 | Actavalon, Inc. | Substituted quinolines and methods for treating cancer |
| FI3612030T3 (fi) | 2017-04-21 | 2026-03-20 | Pahr Therapeutics Inc | Ahr:n indoliestäjiä ja niiden käyttötapoja |
| SG11202001310SA (en) | 2017-08-17 | 2020-03-30 | Ikena Oncology Inc | Ahr inhibitors and uses thereof |
| US11459312B2 (en) | 2017-11-21 | 2022-10-04 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
| WO2019101647A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors |
| CA3082855A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists |
| EP3713931B1 (en) | 2017-11-21 | 2025-03-05 | Deutsches Krebsforschungszentrum | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
| KR20210071976A (ko) | 2018-09-04 | 2021-06-16 | 마젠타 테라퓨틱스 인코포레이티드 | 아릴 하이드로카본 수용체 길항제 및 사용 방법 |
| MX2021004245A (es) | 2018-10-16 | 2021-09-08 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| CA3115825A1 (en) | 2018-10-17 | 2020-04-23 | Magenta Therapeutics, Inc. | Methods of treating cancer with aryl hydrocarbon receptor antagonists |
-
2021
- 2021-01-08 CN CN202180014318.3A patent/CN115190799A/zh not_active Withdrawn
- 2021-01-08 KR KR1020227027399A patent/KR20220125323A/ko not_active Withdrawn
- 2021-01-08 MX MX2022008532A patent/MX2022008532A/es unknown
- 2021-01-08 WO PCT/US2021/012571 patent/WO2021142180A1/en not_active Ceased
- 2021-01-08 AU AU2021206696A patent/AU2021206696A1/en not_active Abandoned
- 2021-01-08 US US17/791,608 patent/US20230039711A1/en active Pending
- 2021-01-08 EP EP21705294.3A patent/EP4087578A1/en not_active Withdrawn
- 2021-01-08 CA CA3167283A patent/CA3167283A1/en active Pending
- 2021-01-08 BR BR112022013673A patent/BR112022013673A2/pt not_active IP Right Cessation
- 2021-01-08 JP JP2022542408A patent/JP2023510797A/ja not_active Withdrawn
- 2021-01-08 IL IL294647A patent/IL294647A/en unknown
-
2022
- 2022-07-08 CL CL2022001872A patent/CL2022001872A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keshavarzi et al. | Molecular imaging and oral cancer diagnosis and therapy | |
| Rivera et al. | Lung cancer in never smokers | |
| Jokilehto et al. | Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. | |
| Schwarzenbach et al. | Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression | |
| Vessella et al. | Tumor cell dormancy: an NCI workshop report | |
| Geavlete et al. | HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer—re-TURBT recurrence rates in a prospective, randomized study | |
| JP2020526206A5 (enExample) | ||
| Tsuji et al. | Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution | |
| AU2020374961A1 (en) | Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (CDK7) | |
| JP2023504786A (ja) | 抗がん効果増進のためのＥＲＲγ抑制剤を有効成分として含む組成物の用途 | |
| Zheng et al. | KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance | |
| ES2914180T3 (es) | Procedimientos y kits para la subtipificación molecular del cáncer de vejiga | |
| JP2015514712A5 (ja) | 発癌物質によって誘発される癌の治療における使用のためのｃｕｒａｘｉｎ | |
| Zhang et al. | KMT2A regulates cervical cancer cell growth through targeting VDAC1 | |
| Shan et al. | Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique | |
| Parvin et al. | Prognostic utility of cyclin D1 in invasive breast carcinoma | |
| Padhi et al. | Cyclin D1 expression in multiple myeloma by immunohistochemistry: case series of 14 patients and literature review | |
| Grote et al. | ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer | |
| JP5413818B2 (ja) | 蛍光多重染色による蛋白定量法 | |
| ATE331958T1 (de) | Verfahren zum nachweis und zur quantifizierung von -aus soliden tumoren abstammenden- zirkulierenden tumorzellen | |
| Yilmaz et al. | Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis | |
| Petrarca et al. | Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer | |
| Cuneo et al. | 13q14 deletion in non-Hodgkin's lymphoma: correlation with clinicopathologic features | |
| JP2015523056A (ja) | Ｉａｐインヒビター治療のためのバイオマーカー | |
| Orta et al. | Radiation-associated extraskeletal osteosarcoma of the chest wall |